UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 598

Sortiert nach

Multi-Omics Profiling Reveals Distinct Microenvironment Characterization and Suggests Immune Escape Mechanisms of Triple-Negative Breast Cancer

Clinical cancer research, 2019-08, Vol.25 (16), p.5002-5014

2019

Link zum Volltext

Verfügbarkeit prüfen

PARP Inhibitors in the Treatment of Early Breast Cancer: The Step Beyond?

Cancers, 2020-05, Vol.12 (6), p.1378

2020

Link zum Volltext

Verfügbarkeit prüfen

RE: NDRG1 in Aggressive Breast Cancer Progression and Brain Metastasis

JNCI : Journal of the National Cancer Institute, 2022-07, Vol.114 (7), p.1046-1047

2022

Link zum Volltext

Verfügbarkeit prüfen

Immunotherapy in Breast Cancer: the Emerging Role of PD-1 and PD-L1

Current oncology reports, 2017-10, Vol.19 (10), p.64-64, Article 64

2017

Link zum Volltext

Verfügbarkeit prüfen

Phosphoinositide 3-Kinase (PI3K) Inhibitors and Breast Cancer: An Overview of Current Achievements

Cancers, 2023-02, Vol.15 (5), p.1416

2023

Link zum Volltext

Verfügbarkeit prüfen

Human breast cancer cells enhance self tolerance by promoting evasion from NK cell antitumor immunity

The Journal of clinical investigation, 2011-09, Vol.121 (9), p.3609-3622

2011

Link zum Volltext

Verfügbarkeit prüfen

PD-1/PD-L1 Targeting in Breast Cancer: The First Clinical Evidences Are Emerging. A Literature Review

Cancers, 2019-07, Vol.11 (7), p.1033

2019

Link zum Volltext

Verfügbarkeit prüfen

How basal are triple‐negative breast cancers?

International journal of cancer, 2008-07, Vol.123 (1), p.236-240

2008

Link zum Volltext

Verfügbarkeit prüfen

Combining poly(ADP-ribose) polymerase inhibitors and immune checkpoint inhibitors in breast cancer: rationale and preliminary clinical results

Current opinion in oncology, 2020-11, Vol.32 (6), p.585

2020

Link zum Volltext

Verfügbarkeit prüfen

RE: HER2DX ERBB2 mRNA expression in advanced HER2-positive breast cancer treated with T-DM1

JNCI : Journal of the National Cancer Institute, 2023-06, Vol.115 (6), p.762-763

2023

Link zum Volltext

Verfügbarkeit prüfen

miR-424(322)/503 is a breast cancer tumor suppressor whose loss promotes resistance to chemotherapy

Genes & development, 2017-03, Vol.31 (6), p.553-566

2017

Link zum Volltext

Verfügbarkeit prüfen

Aldehyde Dehydrogenase 1–Positive Cancer Stem Cells Mediate Metastasis and Poor Clinical Outcome in Inflammatory Breast Cancer

Clinical cancer research, 2010-01, Vol.16 (1), p.45-55

2010

Link zum Volltext

Verfügbarkeit prüfen

Pathological complete response rate and disease-free survival after neoadjuvant chemotherapy in patients with HER2-low and HER2-0 breast cancers

European journal of cancer (1990), 2022-11, Vol.176, p.181-188

2022

Link zum Volltext

Verfügbarkeit prüfen

Targeting BRCA Deficiency in Breast Cancer: What are the Clinical Evidences and the Next Perspectives?

Cancers, 2018-12, Vol.10 (12), p.506

2018

Link zum Volltext

Verfügbarkeit prüfen

Personalized medicine: Present and future of breast cancer management

Critical reviews in oncology/hematology, 2014-09, Vol.91 (3), p.223-233

2014

Link zum Volltext

Verfügbarkeit prüfen

Discontinuation of imatinib in patients with advanced gastrointestinal stromal tumours after 3 years of treatment: an open-label multicentre randomised phase 3 trial

The lancet oncology, 2010-10, Vol.11 (10), p.942-949

2010

Link zum Volltext

Verfügbarkeit prüfen

The therapeutic response of ER+/HER2- breast cancers differs according to the molecular Basal or Luminal subtype

NPJ breast cancer, 2020, Vol.6 (1), p.8-8, Article 8

2020

Link zum Volltext

Verfügbarkeit prüfen

EFA6B regulates a stop signal for collective invasion in breast cancer

Nature communications, 2021-04, Vol.12 (1), p.2198-2198, Article 2198

2021

Link zum Volltext

Verfügbarkeit prüfen

Disulfiram (DSF) acts as a copper ionophore to induce copper-dependent oxidative stress and mediate anti-tumor efficacy in inflammatory breast cancer

Molecular oncology, 2015-06, Vol.9 (6), p.1155-1168

2015

Link zum Volltext

Verfügbarkeit prüfen

Gene expression profiling shows medullary breast cancer is a subgroup of basal breast cancers

Cancer research (Chicago, Ill.), 2006-05, Vol.66 (9), p.4636-4644

2006

Link zum Volltext

Verfügbarkeit prüfen

Prognostic value of PDL1 expression in pancreatic cancer

Oncotarget, 2016-11, Vol.7 (44), p.71198-71210

2016

Link zum Volltext

Verfügbarkeit prüfen

Identification of genetic determinants of breast cancer immune phenotypes by integrative genome-scale analysis

Oncoimmunology, 2017-02, Vol.6 (2), p.e1253654-e1253654

2017

Link zum Volltext

Verfügbarkeit prüfen

Mevalonate Metabolism Regulates Basal Breast Cancer Stem Cells and Is a Potential Therapeutic Target

Stem cells (Dayton, Ohio), 2012-07, Vol.30 (7), p.1327-1337

2012

Link zum Volltext

Verfügbarkeit prüfen

SPAG5 : the ultimate marker of proliferation in early breast cancer?

The lancet oncology, 2016-07, Vol.17 (7), p.863-865

2016

Link zum Volltext

Verfügbarkeit prüfen

Immunologic constant of rejection as a predictive biomarker of immune checkpoint inhibitors efficacy in non-small cell lung cancer

Journal of translational medicine, 2023-09, Vol.21 (1), p.1-637, Article 637

2023

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 598

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(547)
Mit Volltextzugriff
(558)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Journal Of Clinical Oncology
(62)
Cancer Research
(40)
Cancers
(32)
Bulletin Du Cancer
(21)
Bmc Cancer
(16)
Breast Cancer Research And Treatment
(16)
European Journal Of Cancer
(16)
Oncotarget
(14)
Plos One
(13)
Clinical Cancer Research
(12)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

Multi-Omics Profiling Reveals Distinct Microenvironment Characterization and Suggests Immune Escape Mechanisms of Triple-Negative Breast Cancer

PARP Inhibitors in the Treatment of Early Breast Cancer: The Step Beyond?

RE: NDRG1 in Aggressive Breast Cancer Progression and Brain Metastasis

Immunotherapy in Breast Cancer: the Emerging Role of PD-1 and PD-L1

Phosphoinositide 3-Kinase (PI3K) Inhibitors and Breast Cancer: An Overview of Current Achievements

Human breast cancer cells enhance self tolerance by promoting evasion from NK cell antitumor immunity

PD-1/PD-L1 Targeting in Breast Cancer: The First Clinical Evidences Are Emerging. A Literature Review

How basal are triple‐negative breast cancers?

Combining poly(ADP-ribose) polymerase inhibitors and immune checkpoint inhibitors in breast cancer: rationale and preliminary clinical results

RE: HER2DX ERBB2 mRNA expression in advanced HER2-positive breast cancer treated with T-DM1

miR-424(322)/503 is a breast cancer tumor suppressor whose loss promotes resistance to chemotherapy

Aldehyde Dehydrogenase 1–Positive Cancer Stem Cells Mediate Metastasis and Poor Clinical Outcome in Inflammatory Breast Cancer

Pathological complete response rate and disease-free survival after neoadjuvant chemotherapy in patients with HER2-low and HER2-0 breast cancers

Targeting BRCA Deficiency in Breast Cancer: What are the Clinical Evidences and the Next Perspectives?

Personalized medicine: Present and future of breast cancer management

Discontinuation of imatinib in patients with advanced gastrointestinal stromal tumours after 3 years of treatment: an open-label multicentre randomised phase 3 trial

The therapeutic response of ER+/HER2- breast cancers differs according to the molecular Basal or Luminal subtype

EFA6B regulates a stop signal for collective invasion in breast cancer

Disulfiram (DSF) acts as a copper ionophore to induce copper-dependent oxidative stress and mediate anti-tumor efficacy in inflammatory breast cancer

Gene expression profiling shows medullary breast cancer is a subgroup of basal breast cancers

Prognostic value of PDL1 expression in pancreatic cancer

Identification of genetic determinants of breast cancer immune phenotypes by integrative genome-scale analysis

Mevalonate Metabolism Regulates Basal Breast Cancer Stem Cells and Is a Potential Therapeutic Target

SPAG5 : the ultimate marker of proliferation in early breast cancer?

Immunologic constant of rejection as a predictive biomarker of immune checkpoint inhibitors efficacy in non-small cell lung cancer

Suchergebnisse filtern